MBX 바이오사이언시즈(MBX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $63.08 (-1.27%), 시가총액 $1.51B, 52주 최저~최고 $9.73 ~ $43.14.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate,
MBX 바이오사이언시즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
MBX 바이오사이언시즈의 현재 주가는 $63.08 (-1.27%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
MBX 바이오사이언시즈의 시가총액은 약 $1.51B입니다.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its l